Podcasts about Parsons

As the year wraps up, we are replaying some of our favorite conversations from 2025, including this one!What if bankruptcy, a global financial crisis, and other hurdles along the way aren't the end of your brand, but instead a way to help you define what it truly is?Agility requires a willingness to experiment and adapt, not just in your technology stack, but also in your organizational structure and the very culture of your company. It also demands a deep understanding of your customer and a commitment to delivering personalized experiences.Today, we're going to talk about building a resilient brand in the face of uncertainty, balancing the need for both efficiency and innovation, and the critical role of company culture in achieving long-term success. To help me discuss this topic, I'd like to welcome, Shawn D. Nelson, CEO at Lovesac. About Shawn D. Nelson Shawn D. Nelson is the author of Let Me Save You 25 Years: Mistakes, Miracles, and Lessons from the Lovesac Story. He is the founder and CEO of the Lovesac Company, which designs, manufactures, and sells such furniture as modular couches and bean bag chairs. Nelson holds a BA in Mandarin Chinese from the University of Utah and a Master's degree in Strategic Design and Management from Parsons, The New School for Design in New York City, where he later became an instructor. Shawn D. Nelson on LinkedIn: https://www.linkedin.com/in/shawndnelson/ Resources Lovesac: https://www.lovesac.com The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow Catch the future of e-commerce at eTail Palm Springs, Feb 23-26 in Palm Springs, CA. Go here for more details: https://etailwest.wbresearch.com/ Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://ratethispodcast.com/agileConnect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://www.theagilebrand.showCheck out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company

Tonight's call-in show takes an unexpected emotional turn when Kyle from Madison shares the devastating news of his stepfather Doug's sudden passing—the man who made him the Packer fan he is today. Despite his loss, Kyle honored Doug by attending the game with family, delivering a powerful reminder of what football really means to this community. Callers unload on a defense that got absolutely bulldozed by the Ravens, with one fan describing the embarrassing performance from his all-22 vantage point. The Rashaan Gary discussion heats up as multiple callers question his future, noting that Micah Parsons never once gave him props all season—what did Parsons see that we didn't? Plus, Ryan shuts down the Travon Diggs hype train before it leaves the station, reminding everyone that waived players get cut for a reason. The conversation turns philosophical as we examine the "shiny object" fan mentality that always wants to fire someone, trade for someone, and believes everything we have is terrible while everything else is better. This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Projects: Grade NFL Players ➜ fanfocus-teamgrades.lovable.app Packers Hub ➜ packersgames.com Create NFL Draft Big Boards ➜ nfldraftgrades.com Watch Draft Prospects ➜ draftflix.com Screen Record ➜ pause-play-capture.lovable.app Global Economics Hub ➜ global-economic-insight-hub.lovable.app

Tonight's call-in show takes an unexpected emotional turn when Kyle from Madison shares the devastating news of his stepfather Doug's sudden passing—the man who made him the Packer fan he is today. Despite his loss, Kyle honored Doug by attending the game with family, delivering a powerful reminder of what football really means to this community. Callers unload on a defense that got absolutely bulldozed by the Ravens, with one fan describing the embarrassing performance from his all-22 vantage point. The Rashaan Gary discussion heats up as multiple callers question his future, noting that Micah Parsons never once gave him props all season—what did Parsons see that we didn't? Plus, Ryan shuts down the Travon Diggs hype train before it leaves the station, reminding everyone that waived players get cut for a reason. The conversation turns philosophical as we examine the "shiny object" fan mentality that always wants to fire someone, trade for someone, and believes everything we have is terrible while everything else is better. This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Projects: Grade NFL Players ➜ fanfocus-teamgrades.lovable.app Packers Hub ➜ packersgames.com Create NFL Draft Big Boards ➜ nfldraftgrades.com Watch Draft Prospects ➜ draftflix.com Screen Record ➜ pause-play-capture.lovable.app Global Economics Hub ➜ global-economic-insight-hub.lovable.app

All but one doomed to die...thus written in this podcast. How did Martin manage to wrangle A Hamster with a Blunt Penknife out of Joe's hands? Sleight of hands! He switched it back again! Oh audience, is there nobody you can trust these days?

'They are not ice crystals!' Joe & Martin hit their favourite episode of the serial and are deeply moved by the introduction of Binro, and laughing their heads off at Garron's absurdly operatic criminal past.

If you hang that little beauty around your neck you'll never suffer from the scringes, no matter how cold it be! Joe & Martin discover that no one makes a fool of the Graff Vynda K and lives...

Where does your field jacket actually come from? Were WWII soldiers the original hypebeasts? What is the M-43 jacket? Sol and Michael sit down with Avery Trufelman, host of Articles of Interest and 99% Invisible veteran, to break down the military origins of menswear and why everyone's suddenly obsessed with gorpcore. The trio dive deep into the history of the M-65 field jacket, how World War II military surplus shaped American fashion, the invention of layering (yes, someone had to invent it), why Special Forces operators became fashion influencers, and the complicated ethics of wearing military aesthetics as civilians. Further, Avery shares insights from her latest podcast season "Gear," explaining the connection between outdoor brands and military contracts, the decline of army surplus stores, why The Row is making combat boots now, and how Buck Mason's militaria collection tells the story of American style. They also discuss Vivienne Westwood's punk legacy, the upcoming Antwerp Six book, athleisure as health signifier, Rick Owens' influence on tactical fashion, women's gear and the "pink it and shrink it" problem, plus whether military fashion makes you complicit in something larger. Other topics include: the Parsons jacket and Supreme-style military drops, George Doria inventing venture capital AND the field jacket, challenge coins and PowerPoint patch design, Americana Pipe Dream's hunt for rare surplus, Cher and the Armenian diaspora (a future episode?), and why fashion never really goes away — it just cycles back.Want to support the podcast? Subscribe to our HeroHero for giveaways, extra episodes, and more!We hope you enjoy just as much as we did recording!Lots of love!Sol---Episode Tags: Avery Trufelman, Articles of Interest, military fashion, field jacket history, M-65 jacket, gorpcore 2025, menswear history, military surplus, tactical fashion, outdoor gear fashion, American style origins, 99% Invisible, fashion podcast, cargo pants history, Special Forces fashion, athleisure, Rick Owens menswear, The Row combat boots, Vivienne Westwood, punk fashion origins, Antwerp Six, Buck Mason, vintage military clothing, workwear fashion, heritage menswear, Americana Pipe Dream, OG-107 pants, archival fashion, techwear, Stone Island, CP Company, Helmut Lang, fashion trend forecasting, militaria collection, Patagonia military, Arc'teryx fashion, North Face history, functional fashion 2026Sol Thompson and Michael Smith explore the world and subcultures of fashion, interviewing creators, personalities, and industry insiders to highlight the new vanguard of the fashion world. Subscribe for weekly uploads of the podcast, and don't forgot to follow us on our social channels for additional content, and join our discord to access what we've dubbed “the happiest place in fashion”.Message us with Business Inquiries at pairofkingspod@gmail.comSubscribe to get early access to podcasts and videos, and participate in exclusive giveaways for $4 a month Links: Instagram TikTok Twitter/X Sol's Substack (One Size Fits All) Sol's Instagram Michael's Instagram Michael's TikTok

When you solve one real problem brilliantly, it can unlock five more and add an entire category. In this episode of Sharkpreneur, Seth Greene interviews Shawn Nelson, Founder and CEO of LoveSac, who shares how a homemade “not-beanbag” snowballed into a NASDAQ-listed company with 300+ locations, a logistics moat, and the best-selling sectional platform in the U.S. He breaks down the invention mindset, LoveSac's sustainability-by-design philosophy, and why products must be designed for life to win long term. Key Takeaways: → Why logistics matter and how they can be used as your hidden superpower.  → Building a product that can evolve allows it to stay relevant for decades. → Why sustainability and durability beat planned obsolescence.  → Why building your own channel proves demand for your product.  → If products last, growth must come from new rooms, categories, and features. Shawn Nelson is the founder and CEO of LoveSac, Inc. He graduated from the University of Utah and founded LoveSac in 1998, initially creating his first “not-bean bag” from shredded foam camp mattresses. Nelson quickly gained traction, securing an order for 12,000 Lovesacs from Limited Too, and later opening his first retail location in 2001. In 2003, he received the Ernst & Young Entrepreneur of the Year Award. Nelson also appeared on Richard Branson's The Rebel Billionaire in 2005, winning a $1 million investment, and spent three months as acting president of Virgin companies. Shawn expanded LoveSac's product line to include the world's only changeable sectional couch. He earned his master's degree in strategic design and management from Parsons in 2015, where he also became a part-time instructor. That same year, he appeared on Make Me a Millionaire Inventor and delivered the keynote at the 40 Under 40 awards for Fairfield County, Connecticut. In 2018, he took LoveSac public, with shares debuting on Nasdaq under the ticker symbol “LOVE.” Connect With Shawn: Website: https://www.lovesac.com/ Instagram: https://www.instagram.com/shawnoflovesac X: https://x.com/shawnoflovesac LinkedIn: https://www.linkedin.com/in/shawndnelson/ Learn more about your ad choices. Visit megaphone.fm/adchoices

I detta avsnitt möter Bathina Pia Hallström, framstående smyckesdesigner med en internationell karriär som sträcker sig från barndomens skapande i Sverige till modevärldens absoluta topp.Pia berättar om hur hon sydde sina egna kläder som barn, hur nyfikenhet och kreativitet tog henne till studier vid Parsons i New York och vidare till arbete med ikoniska namn som Marc Jacobs och Donna Karan. Men också om kärlek på arbetsplatsen, familjeliv och psykisk ohälsa. Om att våga prata om det svåra, att vara närvarande för sina barn och hur kreativiteten blev både uttryck och räddning. Välkomna! Programledare: @bathina.philipson Produktion: @thepodfather_magnus

We discuss the TNF game between the Rams and Seahawks, the latest on the playoff picture, the Patrick Mahomes and Micah Parsons' injuries, Tua getting benched, and more.

En este cierre de año, Wall Street busca impulso mientras los mercados se preparan para una semana corta por las festividades. Aquí están los temas clave del día:

All but one doomed to die...thus written! Joe & Martin are up to their old tricks again, selling planets, pulling the wool over evil despots and coming from the North!

Episode Description What happens when the career that once defined you no longer fits—or ends entirely? In this episode of the BOSS Business of Surgery Series, host Dr. Amy Vertrees sits down with Elizabeth Parsons, former Wall Street lawyer and author of Encore: A High Achiever's Guide to Thriving in Retirement. Elizabeth shares her deeply personal journey of leaving a prestigious legal career at age 35, only to discover that financial security alone was not enough to replace the identity, structure, and purpose her work had provided. Together, Amy and Elizabeth explore why high-achieving professionals—especially those in service fields like medicine and law—often struggle with retirement or major career transitions. Elizabeth introduces the concept of “identity bridging” and explains why retirement isn't just a financial decision, but a psychological and emotional one. This conversation challenges the idea of retirement as an “ending” and reframes it as a new graduation—an opportunity to intentionally design a next chapter filled with meaning, agency, and fulfillment. If you're a surgeon or professional thinking about retirement, scaling back, or simply wondering “what's next?”, this episode offers powerful insights and practical guidance. What You'll Learn Why high achievers excel as “reactors” but struggle to become “creators” of their own lives The concept of identity bridging and why retirement disrupts more than just your schedule The three motivational pillars of identity: communion, agency, and cohesion Why staying too long can diminish a career—and why “leaving on top” matters How to develop new internal metrics for success beyond professional recognition Why retirement planning should begin at least two years before your exit How to experiment with new interests without needing immediate competence or validation Why succession planning is emotionally harder than most professionals expect Timestamps / Chapters 00:00:02 – Elizabeth Parsons' journey from Wall Street lawyer to retirement transition expert 00:04:21 – From problem-solver to life designer: reactor vs. creator 00:06:06 – Identity bridging and the three motivational properties 00:08:31 – Common pitfalls: why career-adjacent options often fall flat 00:11:11 – Creating new metrics for success without external applause 00:13:46 – Finding your “second curve” and rediscovering dormant interests 00:18:25 – Life restructuring after work: avoiding “365 Saturdays” 00:21:39 – Knowing when it's time to retire—and why leaving on top matters 00:24:53 – Succession planning and the emotional difficulty of handing over the reins 00:32:29 – Elizabeth's programs, intensives, and resources Action Items Begin thinking about retirement or major transitions at least two years in advance Identify how your current identity is tied to belonging, agency, and routine Create personal definitions of a “great day” that don't rely on professional validation Pay attention to persistent annoyance with work—it may be a signal, not a flaw Explore interests with curiosity and experimentation, not immediate mastery Resources & Links Encore: A High Achiever's Guide to Thriving in Retirement by Elizabeth Parsons Learn more about Elizabeth's programs: highachieverretirement.com Connect with Elizabeth on LinkedIn About the Guest Elizabeth Parsons is a former Wall Street lawyer and the founder of High Achiever Retirement. After leaving her legal career early, she experienced firsthand the identity loss that often follows high achievement. Today, she helps accomplished professionals navigate retirement and major career transitions with intention, clarity, and purpose.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAAs we talk about the gene transfer therapies and the modalities that we have to use, it's really interesting. Yesterday, with our keynote speaker, you could see this logarithmic growth of the use of gene transfer therapies for these disorders. If you look at the Venn diagram, you can see that really 27% almost of gene transfer therapies that are used are in musculoskeletal and neurology. For many of us as neurologists, we also take care of metabolic disorders.We really own right now this landscape, and of course, our two approved modalities are Onasemnogene and Delandistrogene. We're going to look at three different disorders, monogenic disorders, monogenic diseases, to typify what we look at in terms of some of the risks and benefits of these treatments. SMA, Duchenne, and X-linked myotubular myopathy are all rare disorders. They're all diseases that have a high unmet medical need and a significant disease burden.I think they're all good in terms of typifying where we are clinically with these disorders. The first question is, is it worth it? Are these effective treatments? We know from looking at the information about SMA that just looking early on, we know that if we treat kids early, that we do see a marked improvement in motor scores for kids that are treated early with Onasemnogene.In Duchenne, we have information that there is at least some improvement in the 4-5-year-olds in terms of motor skills treated with Delandistrogene. In terms of X-linked MTM, which was a very dramatic improvement, you could see that for boys who were basically traked, vented, and had no mobility, the bottom line, the blue line, is actually looking at ventilator dependence. Are they effective? Yeah, they're effective, but then we have to say, okay, what's the downside?The downside is that there's tremendous risk associated with treatment with these agents. If we really look at the sobering facts, we know that with SMA, there have been deaths, there have been fatalities related to thrombotic microangiopathy to patients who have liver failure, a couple of patients have died. With Onasemnogene, this is 4,000 plus doses that have so far been given. With Duchenne, unfortunately, many of us got the letter yesterday talking about an additional death in a patient treated with commercial Delandistrogene.We also know with some of the other agents, like fordadistrogene, patient died of heart failure, cardiac arrest, another patient who had acute respiratory syndrome with pulmonary edema. Again, we look at this and say this is significant. With X-linked MTM, as Alan said, there were some unanticipated deaths, four deaths from patients who ended up having cholestatic liver diseases that really wasn't anticipated prior to the patients being treated with the animal models and all that we had. Then many of you have heard about the patient with Rett syndrome who had a systemic hyperinflammatory syndrome. Again, these are rare disorders. They have a high disease burden, but the risk of treatment is significant.In the next part, Dr. Parsons discuss factors impacting safety and efficacy of AAV-mediated gene therapies.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe ASPIRO Clinical Trial is on clinical hold since September 2021. In this part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.Question: Is there a standardized immunomodulation regimen being considered for gene therapy?Julie A. Parsons, MDAs I mentioned, right now, I think there are a number of different concepts that are being utilized. We don't really have a recommended standard regimen at this point. There are a number of different trials that are ongoing looking at trying to answer this question. In some of the clinical trials, there is an immune modulating regimen that is being put in place but being looked at. There isn't anything that we have as a standard at this moment for all gene transfer therapies, but I'm hopeful that we will come up with something that really makes sense in each patient population as we go forward with specific gene transfer therapies.Question: What are the long-term implications, safety and efficacy of a one-time gene therapy in pediatric patients with neuromuscular diseases?Alan Beggs, PhDOne question is the efficacy. For example, Donovan Decker's story, he had an experimental treatment of one muscle. It was a phase one safety trial, and he knew that nothing was going to come of it in terms of direct benefit to him. As a result, though, 25, 30 years later, he still has a tighter against AAV vectors. He's not a candidate for gene therapy under current protocols, although there's a lot of work going on to redosing. But for now, it's a one-time treatment. What you get is what you get, and there's not a chance to go back and do it again.The other question is durability. We really don't know about the long-term durability for these treatments. I should say that, for example, in the studies that we did, David Mack, who's here in the audience, managed a dog colony for a dog model of excellent tubular myopathy. Those animals lived 10 years in a... We never used the C-word, but they were cured. They were healthy, happy, normal dogs who would have had to be put down at 6 months of age otherwise. And then, as we heard, I'll let you talk about the concern for unanticipated SAEs as time goes on, but I think there's other aspects we need to think about.Julie A. Parsons, MDYeah. I think that this is really the key question that all of us are going to need to help answer over the next several years. Efficacy, we're looking at outcomes, and outcomes come in a variety of flavors. I think we do a decent job with motor outcomes. We don't do a decent job with some other outcomes. I think we need to look more broadly in terms of what we mean in terms of beneficial outcomes and really take some of those cues from the patients themselves about if these are efficacious treatments, because, again, the risk is high as we deliver these agents, and we need to know that it's worth it to the patients and families.In terms of safety, we're working on it. There are all sorts of things that are coming forward as issues with these patients. I think that collectively as a community, that our responsibility is to follow patients for the long term. There are lots of registries and outcome studies. We're not very good as a community about reporting adverse events to central groups. We're not great about broadcasting that to each other in real-time. I think those are things that we really need to work on as a community in terms of helping with the safety issues so that we all have a communal better understanding of what some of those issues are.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAHow have programs adapted to the experiences from clinical trials? I'm just looking at SMA because we've had SMA. We've had onasemnogene around for the longest period of time. We want to always confirm a diagnosis and know that the patient is right. We do antibody testing for these disorders prior to delivering the AAV therapies. We have to know that the product that is incredibly expensive is handled appropriately by the institution. Dealing with the pharmacy, making certain that you handle the agent properly, patients need to be pretreated at this point with prednisone, and that really has to happen so that you know that they're ready for treatment, that they don't have any infections prior to treatment.Then we need to monitor and provide medication and follow-up afterwards. As I said, I think this is really, really important to make sure that you're connected well with the patient. If you live in an area as we do, that has a huge catchment area with patients that come from hundreds of miles away, sometimes they need to stay with us for a period of time, so that we can ensure the safety and follow-up of these patients after we deliver gene therapies.Again, a recurring theme is the patients that you're treating who are not in a clinical trial are not the homogeneous, well-selected patients. It's really all actors. The population that you're treating commercially is very different. We're now moving into treating patients with larger body masses and older ages. We don't always know, because those patients haven't really been included in the clinical trials. We don't really know what some of the effects are going to be with that group of patients as well.I am a neurologist. I am not an immunologist. I have had to learn a lot of immunology at this point, but it's still not sufficient. I think that we also need to reach out to our subspecialist colleagues who really do have more experience than we do to try to help us with some of these issues, because as we look at these viral vector capsids and the transgenes, we have to say, is there something that we can do to mitigate the immune response that we're seeing when we're giving massive doses of these agents and really taxing the immune system in our patients?Looking at possibilities, we give steroids, and that's really what we've done. That was what was done in the early clinical trials with MENDEL. It's like, okay, prednisone, that's all we have to do is we give steroids and everybody will be fine. That really isn't maybe the answer. As we have more information, we know that we're going to start with steroids, but we're really going to look at, is there a way to block both the B-cell response, the T-cell response? Is there something that we can do so that we don't have to sit on the edge of our seats and not sleep for months after we treat these patients?At least in a trial, was done looking at patients who were treated just with corticosteroids. Those patients had rapid increases in IgM and IgG. There's complement activation. Both the adaptive and the acute immune responses are triggered. That's really what we're doing as standard practice right now, but in the trial looking at treating patients and pretreating patients with rituximab blocking B cells and sirolimus and corticosteroids, then no significant change in IgM, IgG.Is that something that we should be doing? I think that some of the clinical trials that are being set up are looking at instituting some of these immune-modulating features to see whether or not their outcomes are improved. Can we do anything proactively to prevent our patients from having some of these very severe events or fatalities? I think that's really what we need to be looking at now. I think we are looking at that as a community, and to me, is a story that is still unfolding in terms of how we keep our patients safe.In the next part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.

Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe gene transfer trials for musculoskeletal disorders, if we look at musculoskeletal and neurologic disorders, we really do have the highest success rate in terms of treatment, but we also carry the highest incidence of treatment-emergent severe adverse events. And why is that true? Yesterday, when we were hearing about Donovan as well, we looked and said, When the first gene transfer therapies were started, he had a single muscle that was injected.When we look at Luxturna, we injected the retina. Now, what is happening with these disorders is that we're giving these huge, massive doses of viral vector to patients. There haven't been a lot of gene transfer therapies that have reached the market. But you saw yesterday, so many gene transfer therapies being worked on, but there are very few that have actually come to market. There are a couple of reasons for that.One is with the indications that we have, we know that the musculoskeletal disorders are most likely to achieve benefit, but there are the high risk of severe adverse events. Route of Administration, IV, for most of our disorders is the way we're going. We may end up having some Intrathecal therapies as well that are coming on board, but right now it's IV, and that means, a huge dose of this viral vector and antigenic risk that is being administered.In the vector design now, we actually have more specific vectors as well as promoters that are being utilized to really target specific tissues, so that we're able to focus in a little bit more on the tissues that we want to have affected. And then the dose has gone from these little tiny local injections to really systemic, much broader. And now our patients, are larger. So we're giving a viral genome per kilo dose that is just massive as we look at that.Then there really are challenges in terms of the translation of clinical trials to commercial treatment with these agents. And we don't always know, we're not always great when we do tests in clinical trials in small populations, about when that's broadened to the commercial availability and we hit larger heterogeneous populations.There are safety issues arising from these therapies, and I think that we have some experience now, certainly with the three diseases that I mentioned at the beginning, in terms of collecting some data and information to have a little bit more of an idea what to expect. Although to me, the recurring esteem is always, expect the unexpected. Because we still are learning about this. Hepatotoxicity. We know that transaminitis is something that we see in almost every gene transfer therapy that has been delivered, and we have to watch really, really closely and follow our patients closely for this. We also have to select patients that we don't think have risk for additional liver injury or underlying liver pathology, because as we found out in the XLMTM boys, we missed that. Thrombotic Microangiopathy. We look at this disorder. We've had deaths in SMA from TMA. We have Duchenne patients that have had TMA.This is scary because as many of us as clinicians who have treated patients, you know that we end up getting thrombocytopenia. So is that it this time, or are they going to be fine, or the platelet is going to go back to normal? This is another one that we have to watch really, really closely for. Cardiac Toxicity. We have had cardio myositis. We've had deaths from cardiac toxicity.Something really, really important for us to think about. In little kids, vomiting could be a sign of cardiac myositis. And for most of us who've treated patients with gene transfer therapy, what's one of the first issues that you get?You get nausea of vomiting, they don't feel good. So is that myocarditis or is it just a standard side effect that we're seeing with treatment? Importantly, as we discovered, there actually can be an immune response to the transgene. It's not just the viral vector capsid, it's actually the transgene as well. That was discovered in patients who were treated for Duchenne. So that's a really important thing in terms of looking now at what's our patient's selection and how do we pick the right patients.Next part, Dr. Parsons will discuss understanding and preparing risk factors associated with AAV gene therapies.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USAThe challenges that you've heard about are real. Some of them I think we could have foreseen others. There was no way to know until we actually started treating patients in clinic. But we now know that there are immune responses and also responses just to the viral load. As Julie mentioned, we're giving massive doses to these patients on the order of one times ten to the 14 viral genomes per kilogram.Think about the fact that when these capsids are manufactured, there's a certain percentage of empty capsid. The amount of protein that's being delivered to these patients can be massive. One of the approaches to mitigate some of the risk would be to lower the dose. While early studies demonstrated that in order to get adequate delivery to skeletal muscle, you need to give these very large doses. But what if we could engineer a viral capsid that would be potent at lower doses?There has been quite a bit of research in this area that's ongoing, and some new next generation vectors that are just starting to enter the clinic. In particular, there are a class of Myotropic viral vectors or capsids so-called RGD vectors. RGD refers to arginine, glycine, and aspartic acid, which are three residues which, when present at a particular point in the viral capsid proteins interact with integrin receptors that are specific for skeletal muscle. These viral capsids home to skeletal muscle and can deliver their genetic payload at much lower doses. There was one group of these developed in Germany by Theo Grimm's lab.These were the so-called AAV Myos, and simultaneously in Boston at the Broad Institute, a group of capsids was developed that were called Myo AAV. These were both based off of an AAV nine backbone. It's basically an AAV nine legacy vector with these three amino acids changed. Now Solid Biosciences also has their own independently derived vector that I believe is also an RGD vector. These vectors give us the potential then for more efficient and specific delivery to muscle cells.They may or may not target the liver depending on the particular virus. Some of them the risk to the liver is mitigated by delivering a lower dose. You can also develop these vectors in a way that will be liver targeted, that specifically less of it gets delivered to the vectors. These would be really, in my mind potentially third generation vectors.Strategies, there are a number of strategies. You heard about the immunomodulation regimens. I just talked about optimizing vector design. Also, Doctor Parsons mentioned earlier the fact that where you deliver so zolgensma is delivered Intrathecally. We get it to the place we need it, and we're less likely to have off target effects through other tissues.Then improved manufacturing is very important. I mentioned the fact that every viral preparation contains empty capsids. There are ways to minimize the production of empty capsids, and also effective ways to filter out and remove those empty capsids. This is actually a very important aspect that is being developed further by the CMO community. Then in summary, I think it's important to take a holistic approach when we're thinking about the development of AAV based gene therapies for neuromuscular disease.It starts from the fact that for any given disease we're interested in, we need to define the genetic etiology. Since these are gene directed therapies. We need to pay careful attention to the preclinical animal models. How accurately do they really reflect the human condition? Or are there potentially responses in our human patients that we haven't experienced in the animals? It's important to understand the natural history and the patient population.Recognize that there's extensive heterogeneity, not just in age and severity, but also potentially in underlying susceptibilities in our patients. We have a group of toxicities that we know about and can anticipate. But as Julie was saying, you need to be really careful and think about any potential unexpected SAEs. And then finally I mentioned the manufacturing aspect, the development of newer vectors and quality control aspects that go into making a safe and effective therapeutic.In the next part. Doctor Parsons will discuss clinical safety and efficacy observed in AAV mediated gene therapy programs in DMD, SMA, and XLMTM.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USADoctors Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established. In contents of this podcast, shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021.In this part, Doctor Beggs will provide an explanation of AAV-mediated gene therapies.Alan Beggs, PhDAAV vectors, which I'm going to be talking about more today, or Adeno associated viral vectors are small viruses. Their DNA gets delivered into the cell and remains extrachromosomal. There are very rare occasional integrations, but the risk of oncogenesis as a result is significantly lower as a consequence of remaining extrachromosomal, though, we do have to think about what happens as the cells divide and potentially the durability of treatment is more limited.There have been a lot of movement and development over the years, starting back in the 1980s when the first AAV genomes were isolated and sequenced. This led to a development of methods to produce recombinant AAVs that would lack the genes necessary for viral replication, but contain a therapeutic gene you wish to deliver. Through this, the structure of AAVs have been developed. There have been isolation of a number of naturally occurring variants. You've heard of AAV8, AAV9, also RH 74, derived from a rhesus monkey for the RH. These have all been used in clinical trials. Then at the end I'll talk a little bit about directed evolution methods to actually engineer capsids with particular properties that are beneficial.Throughout this we've identified some of the issues that arise in this. It was initially thought that AAV vectors were non-immunogenic, but in fact there are immune responses not just to the viral payload to the therapeutic protein, but also to the viral vectors, and you're going to hear about that from Doctor Parsons. Over time, as we've come to understand these challenges, we've also been developing approaches to mitigate them. In terms of clinical trials and treatments, the very first studies were done back in the 1970s.By the early 2000, the very first clinical therapeutic was approved in China. It was actually an oncolytic virus carrying a p53 gene to treat head and neck cancers. By now there are over 40 approved treatments for various types of AAV delivered gene therapies. Of course, the ones we know a lot about are Zolgensma, which was approved in 2019, and Elevidys, which was approved last year. A number of challenges and then also a number of approaches to overcome those challenges. First of all, the preclinical data are not always sufficient to predict the response of a human patient.For example, in X-linked myotubular myopathy we had mouse and dog models that exhibited a myopathy but nothing else, and yet when we treated human patients, we discovered that patients with X-linked myotubular myopathy actually had a previously only poorly recognized hepatopathology that led to potential liver consequences following gene therapy. The animal models don't always predict the clinical outcome in humans.Also, we have small disease populations. These are rare diseases. It's important to understand the natural history of these diseases, understand the heterogeneity among the clinical population. It's very important to engage with families and with patients and communities, understand who might be at increased risk to treatment with one of these. This feeds into safety considerations. We need to think also about some of the immune responses. I think we're starting to learn, for example, with the gene therapies for Duchenne, and we know this from SMA that some patients get into trouble and others don't. We need to understand why that may be, and we don't know about the long term effects. This has been very recent.

Drs. Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established in contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021. In this part, Dr. Beggs will provide an introduction to gene-directed therapies.Alan Beggs, PhDI'm going to talk now about challenges, a little bit of background in the history and the development of AAV-mediated gene therapies, in particular for neuromuscular disorders. There are a lot of aspects about neuromuscular disease that make it a good group of conditions to target by gene replacement therapies. These are traditionally single gene disorders with known identified oftentimes protein deficiencies, so null mutations leading to lack of a protein.The primary tissue, the therapeutic target is a skeletal muscle, and so we can target that with the appropriate viral vectors. There's a major unmet medical need and substantial clinical burden for these conditions. As rare diseases, they place a very substantial burden on both health systems and patients, both economically and in terms of personal difficulties.I like to think about gene therapy, which is generically used for one category of this, to really think about gene-directed therapy. So this would be any therapy directed at the nucleic acids that are either encoding our DNA or are encoding the messenger RNA transcripts. So one approach to a gene-directed therapy can be directed at the RNA level. I think you're all familiar with the Exon-skipping approaches that target mRNA splicing.There are other methods for either knocking down toxic gain of function messenger RNAs, and there are methods now being developed to edit messenger RNAs. So this represents one class of gene therapy. You can also approach gene therapy at level of DNA by editing or changing the DNA in situ. So various CRISPR-Cas9-based approaches. There's now prime editing and other approaches for genetic engineering that target specific locations, often using bacteria endonucleasis that target with oligenucleotides that target specific sites.And then finally, there's gene replacement therapy, which is what we're going to spend most of our time on today, which really aims to not take away what's there and replace it, but to replace the missing protein product by providing a copy of the healthy or the complete wild type gene. Often, it can either be integrated into the chromosomes or remain extrachromosomal.So whether or not that happens really depends on the type of vector or approach you use. You can see here a number of different approaches for transferring in a therapeutic gene. The two most commonly used in clinical trials are lentivirus and AAV, and they have different strengths and weaknesses. Lentiviruses are used frequently for hematologic diseases.Lentivirus is a member of the retrovirus family and has the characteristic that it actually integrates into the DNA. So lentiviral treatments tend to be long-acting. However, they also suffer from the risk that by integrating into the DNA, you might have site-directed mutagenesis. And there have been known instances of cancers that arose through integration at the wrong site.In the next part, Dr. Beggs will cover the history and challenges in the development of AAV-mediated gene therapies.

The callers brought the fire tonight. With the Micah Parsons injury still fresh, Packer Nation called in not to mourn but to rally. This might be the most fired-up After Dark episode of the season. Randy from Minnesota dropped a Thomas Paine quote from 1776 that stopped the show cold: "These are the times that try men's souls. The summer soldier and the sunshine patriot will, in this crisis, shrink from the service of their country." The parallels to fair weather Packers fans hit hard. Kyle from Madison made the case for Jeff Hafley to unleash an entirely new aggressive defensive scheme against Chicago since the Bears have zero tape on a Parsons-less defense. Beer Cheese Bane and Chris from Alabama delivered passionate speeches about why this team still has everything it needs to make a run. The conversation also covered Matt LaFleur's substitution patterns, why quarterbacks keep having career games against Green Bay, and the reality that Saturday's Bears game is essentially a playoff game for the NFC North title. If the Packers win, they're back in the driver's seat with the easier remaining schedule. Time to lock in. This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Projects: Grade NFL Players ➜ fanfocus-teamgrades.lovable.app Packers Hub ➜ packersgames.com Create NFL Draft Big Boards ➜ nfldraftgrades.com Watch Draft Prospects ➜ draftflix.com Screen Record ➜ pause-play-capture.lovable.app Global Economics Hub ➜ global-economic-insight-hub.lovable.app

The callers brought the fire tonight. With the Micah Parsons injury still fresh, Packer Nation called in not to mourn but to rally. This might be the most fired-up After Dark episode of the season. Randy from Minnesota dropped a Thomas Paine quote from 1776 that stopped the show cold: "These are the times that try men's souls. The summer soldier and the sunshine patriot will, in this crisis, shrink from the service of their country." The parallels to fair weather Packers fans hit hard. Kyle from Madison made the case for Jeff Hafley to unleash an entirely new aggressive defensive scheme against Chicago since the Bears have zero tape on a Parsons-less defense. Beer Cheese Bane and Chris from Alabama delivered passionate speeches about why this team still has everything it needs to make a run. The conversation also covered Matt LaFleur's substitution patterns, why quarterbacks keep having career games against Green Bay, and the reality that Saturday's Bears game is essentially a playoff game for the NFC North title. If the Packers win, they're back in the driver's seat with the easier remaining schedule. Time to lock in. This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Projects: Grade NFL Players ➜ fanfocus-teamgrades.lovable.app Packers Hub ➜ packersgames.com Create NFL Draft Big Boards ➜ nfldraftgrades.com Watch Draft Prospects ➜ draftflix.com Screen Record ➜ pause-play-capture.lovable.app Global Economics Hub ➜ global-economic-insight-hub.lovable.app

End of Chiefs era. Mahomes & Parsons lost. CFP is here. 68 Ventures bowl game breakdown (-: Fun!

Ben Solak returns to talk Week 16, Miami's QB options, Trevor Lawrence's massive opportunity in Denver, and how all of Green Bay's injuries will impact the Packers-Bears rematch before talking about which birds he has been looking at outside his window. (00:00) Intro(02:54) Bengals-Dolphins(13:24) Jaguars-Broncos(20:29) Packers-Bears(28:29) Eagles-Commanders(36:34) 49ers-Colts(41:11) Punishment update(47:56) Bucs-Panthers(52:29) Patriots-Ravens(59:10) Raiders-Texans(01:01:44) Bills-Browns(01:02:22) Chargers-Cowboys(01:04:15) Chiefs-Titans(01:07:38) Vikings-Giants(0127) Jets-Saints(01:14:10) Falcons-Cardinals(0120) Ringer 107 Picks Discord link: https://discord.com/invite/WdtQNSdDUc Check out the 2025 Ringer Fantasy Football Rankings: https://fantasyfootball.theringer.com/ Email us! ringerfantasyfootball@gmail.com Hosts: Danny Heifetz, Danny Kelly, and Ben SolakProducers: Kai Grady, Carlos Chiriboga, Ronak Nair, and Ryan Garcia This episode is sponsored by Chime. Bank Smarter, Progress Further. The Ringer is committed to responsible gaming. Please visit www.rg-help.com to learn more about the resources and helplines available. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

Jen Kirton joins Monte and Erin to preview the Packers-Bears showdown in Chicago. They talk about what nthe post-Parsons defense might look like, what injuries concern them most, and how the teams match-up against each other. They also give their score predictions and debate how the Packers match-up in the NFC.

On this episode, James Weaver, Matt Manocherian, and Alex Vigderman convened to discuss the impact of the injuries to Micah Parsons, Davante Adams, and Patrick Mahomes.They addressed both the impact the injury will have on their team and potential playoff positioning (for the Packers and Rams) and what the player is likely to look like when he comes back (it can take a little time to build back up to full skill).ArticlesWhat to expect from Adams and Parsons coming off their injuriesWhich NFL teams were most and least impacted by injuries (as of Dec. 3) Off The Charts features a blend of statistical insights, tactical analysis, and personal opinions, aimed at providing listeners with a comprehensive understanding of the week's key matchups and the intricacies of the sport. You can follow our content on Twitter at @Football_SIS, on Bluesky at @sportsinfosis.bsky.social and at sportsinfosolutions.com.

Week 16 of the 2025 NFL season is here, and the Missing the Point crew unloads on one of the most chaotic weeks the league has seen in years. Dave, Mike, Bobby, and Rayshawn break down the fallout from a Week 15 that completely reshaped the playoff picture and may have permanently altered multiple franchises. It starts with the injuries. The ACL gods showed no mercy. Patrick Mahomes is done for the season, ending the Chiefs’ playoff hopes in brutal fashion. Micah Parsons goes down, ripping the heart out of Green Bay’s defense. Davante Adams, Devin Neal, and several other key contributors leave games early, forcing contenders to scramble as the season enters its final stretch. The crew debates whether this was bad luck, bad field conditions, or just the inevitable price of a longer and more violent NFL season. Then comes the moment that broke everyone’s brain. Philip Rivers is back. The Colts are handing the offense to a quarterback who retired years ago, and the crew reacts with disbelief, laughter, and real football analysis. Is this desperation or genius. Can Rivers still read defenses. Can he survive a hit. And what does this say about the Colts’ confidence in the rest of their roster. From there, the episode hits the Cowboys’ slow collapse, the Chiefs being mathematically cooked, the Ravens living dangerously on the playoff bubble, and the Panthers, Texans, and Steelers trying to survive December football. The Patriots winning streak came to an end, thanks to a dreadful defenseive preformance in the second half vs the Bills, while the Broncos continue to look like the most complete team in the league. The episode closes with a full breakdown of the Real BK Top 10 Power Rankings heading into Week 16. Texans, Chargers, Jaguars, 49ers, Bears, Seahawks, Patriots, Bills, Rams, and Broncos. Every spot is debated, every rise and fall explained, and no team is safe from criticism. If you want real NFL conversations, sharp humor, and power rankings that actually react to what happens on the field, this episode delivers. Follow Missing the Point:Website: https://www.mtpshow.comYouTube: https://youtube.com/@MTPPodX: https://twitter.com/MTP_podInstagram: https://instagram.com/MTP_podTikTok: https://tiktok.com/@MTP_podFacebook: https://facebook.com/MTPPod

Sunday in Denver was the definition of heartbreak, not just because we lost, but because we watched the season change in a single stretch.We were up 23–14 and controlling the game… then everything flipped. A key pressure leads to the interception, Christian Watson goes down, and soon after Micah Parsons suffers what looks like a torn ACL. From there, the preventable mistakes piled up: dumb penalties, dropped interceptions, mental errors, and missed opportunities that handed Denver life, even though we still had every chance to win.But this episode isn't just about the Broncos loss. It's about what the injuries exposed.We break down why the offseason and the last three drafts have left us with too little reliable depth when it matters most, and why the failure to consistently hit on Day 1 and Day 2 picks is now showing up in the worst possible way.Then we pivot to what's next: Saturday night in Chicago.Even with all the chaos, we're still in position to clinch the playoffs, and we're still alive in the North race. But we're going to need a new defensive approach without Parsons, a smarter plan to contain Caleb's right-side escape lanes, and an offense that wins with field position, motion, jumbo sets, and disciplined decision-making.Can we play perfect to beat the Bears?

Charlie and Mitch get together for another edition of the Tapping The Keg Podcast where they cover the Green Bay Packers, Milwaukee Bucks and Wisconsin Sports in 2026. The podcast begins with the boys discussing the fallout from the Micah Parsons injury. Where do the Packers go from here? Are they still contenders? When should we expect Micah back? They also break down what the defense should look like against the Chicago Bears next week. From there, they talk about Doc Rivers being on the hot seat and if it's justified plus they get into all of the things that are happening with the Milwaukee Bucks. Finally, why unknown should be the 2026 word for Wisconsin Sports.

Bo Nix and the Denver Broncos are under fire from NFL analyst Ryan Clark due to Green Bay Packers superstar pass rusher Micah Parsons tearing his ACL at Denver's stadium. Clark claims Nix is to blame for Parsons' injury. Bo Nix also now has the second best odds to win NFL MVP and is drawing top-10 QB rankings following his impressive Week 15 showing. Is the Houston Texans defense REALLY better than Denver's? There's reason to believe the Broncos' defense is much better. Los Angeles Rams WR Puka Nacua also says the Broncos will be in the Super Bowl in February. Stay until the end for a Denver Broncos vs Jacksonville Jaguars Week 16 preview!Join the Broncos Avenue community to receive exclusive perks! Get early access to videos, ad-free episodes, special badges and MORE: https://www.youtube.com/channel/UCVaN0vAKhNky_bhTwW1VQFQ/joinWant us to cover MORE Denver Broncos news? Subscribe: https://www.youtube.com/@BroncosAvenue?sub_confirmation=1Socials: https://linktr.ee/broncosavenue

It's Fox Sports Radio's official fantasy football podcast! Dan Beyer and Mike Harmon open this midweek edition of the show discussing the league-shaking injuries to Patrick Mahomes and Micah Parsons... How does each affect the fantasy landscape rest of season? Then they start looking ahead to Week 16, previewing the marquee Thursday Night Football matchup between the Rams and Seahawks. Plus, producer Ian shares an unfortunate fantasy experience from this past week. Hosts: Dan Beyer, Mike Harmon Producer: Ian Roddy #fsrweekends #jssSee omnystudio.com/listener for privacy information.

Can the Packers win without Parsons I say Yes.themattramage.com

It's Fox Sports Radio's official fantasy football podcast! Dan Beyer and Mike Harmon open this midweek edition of the show discussing the league-shaking injuries to Patrick Mahomes and Micah Parsons... How does each affect the fantasy landscape rest of season? Then they start looking ahead to Week 16, previewing the marquee Thursday Night Football matchup between the Rams and Seahawks. Plus, producer Ian shares an unfortunate fantasy experience from this past week. Hosts: Dan Beyer, Mike Harmon Producer: Ian Roddy #fsrweekends #jssSee omnystudio.com/listener for privacy information.

Michael Wilbon and Tony Kornheiser discuss Mahomes, Parsons, and Philip Rivers. Learn more about your ad choices. Visit podcastchoices.com/adchoices

First Take begins with the battle for the AFC North. Rodgers has the Steelers in front with three game remaining and a week 18 slugfest looming. Who will become the King in The North? And, Can the Packers go far without Parsons? (0:00) Then, Chris Canty tells us why the Chiefs need to stop taking Mahomes greatness for granted. (22:10) Finally, Josh Allen showed us he still carries the torch as he lit fire to a snowy Foxborough. Do his Bills need to win the division more than Drake's Pats? (41:30) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Sheil is joined by Seth Walder from ESPN to dive into the crucial data surrounding some of the biggest hot-button topics buzzing around the NFL. (00:00) Three numbers: The MVP race, the Parsons injury, and Seahawks-Rams(1:22) The MVP betting odds(9:14) Micah Parsons's pass rush win rate for the Packers(16:30) Rams vs. Seahawks playoff ramifications(26:42) The Hurry Up: The end of Patrick Mahomes's second phase Shopping. Streaming. Celebrating. It's on Prime. The Ringer is committed to responsible gaming. Please visit www.rg-help.com to learn more about the resources and helplines available. Host: Sheil KapadiaGuest: Seth WalderProducer: Chris SuttonSocial: Kiera Givens and Brian WatersProduction Supervision: Conor Nevins and Arjuna Ramgopowell Learn more about your ad choices. Visit podcastchoices.com/adchoices

SVP and Stanford Steve are back to break down Week 15 of the NFL season. The guys start off with a Pittsburgh & MNF recap, and surprise, SVP was prepared for the cold this time! The Chiefs are eliminated, but don't declare the dynasty 'over' just yet. The 49ers continue to win and fly under the radar, and the NFC West has yet another big game Thursday as the Rams visit Seattle. Plus, who will win the NFC South? Who will win the AFC North? All that and more including Pooptown update, remembering baseball cards, a CFP first round preview, the state of college basketball and more. Time Codes/Topics (0:00) Intro (0:36) Pittsburgh recap (10:30) Chiefs eliminated reaction (11:50) Who is the team to beat in the AFC? (13:10) Looking back on KC's run (17:10) Stop declaring things over (22:30) Parsons fallout for GB (25:25) LAR-SEA is a big one, again (27:35) Phil Rivers return reaction (32:35) 49ers keep winning (35:25) Who will win the AFC North? (37:40) Who will win the NFC South? (40:40) Current residents of Pooptown (51:00) Watch King of Collectibles (1:01:18) CFP 1st rd preview (1:07:58) Thoughts on the state of CBB (1:16:41) Nikola Jokic is unreal (1:19:00) Wizards update (1:20:50) More CBB thoughts (1:24:45) Thanks for watching Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today on the "Tuesday Morning Running Back" edition of the podcast for December 16, 2025:Chapters:(01:27) - Matt's surprise 40th birthday trip(07:03) - Patrick Mahomes/Micah Parsons injuries(12:41) - Grieving injuries as an NFL player(18:30) - 44 y/o Philip Rivers is back in the NFL!(24:55) - Bears/Packers preview(33:24) - Matt's Workhorse of the Week(38:10) - What we learned at churchWant to advertise with us? Have a question? Got a guest suggestion? - Email us - jason@sportsspectrum.comWATCH all of our podcast episodes on our YouTube page:https://www.youtube.com/SportsSpectrumMagazineSign up for our Sports Spectrum Magazine and receive 15% off a 1-year subscription by using the code PODCAST15https://www.theincrease.com/products/sports-spectrum-magazine 

Another week, another massive injury for dynasty IDP managers. This time, it was Green Bay star edge rusher Micah Parsons tearing his ACL. Parsons joins Fred Warner, Nick Bosa, Brian Branch, and other IDP stalwarts who've been lost for the 2025 season due to injury. Adam, Bobby, and Josh discuss Parsons' dynasty value in light of the injury, then recap all the notable developments at LB, DL, and DB in Week 15.0:00 Addie is Sweating MNF (Again)4:17 Micah Parsons Injury16:13 LB Developments41:20 DL Developments1:08:45 DB DevelopmentsCheck out our brand-new, free IDP start/sit tool, powered by Mike Woellert's weekly projections: https://idpstartsit.com/Subscribe to our YouTube channel for our other shows, The IDP After Show and All IDP.If you'd like to support the show, you can do so for just $5/month over at ⁠theIDPshow.com⁠. We've got some premium features for paid supporters that we know you'll enjoy. Follow us on Twitter ⁠@theidpshow⁠. Thanks for listening!

See omnystudio.com/listener for privacy information.

Gregg Rosenthal is joined by Jourdan Rodrigue, Nick Shook and Patrick Claybon to recap all of the Week 15 action from around the NFL starting with the Chargers at the Chiefs followed by Packers at Broncos (13:00), Bills at Patriots (24:20), Lions at Rams (34:57), Colts at Seahawks (43:40), Ravens at Bengals (53:05), Cardinals at Texans (01:02:56), Jets at Jaguars (01:11:30), Raiders at Eagles (01:17:30), Titans at 49ers (01:23:00), Commanders at Giants (01:29:20), Browns at Bears (01:34:55), Panthers at Saints (01:41:00), and Vikings at Cowboys on Sunday Night Football (01:48:10). Note: time codes approximate. NFL Daily YouTube: https://www.youtube.com/nflpodcastsSee omnystudio.com/listener for privacy information.

Packers fans, what an entertaining, yet gut-wrenching game yesterday vs the Denver Broncos. The first half was going good, but then the wheels fell off for Green Bay. Diving into the game recap, latest surrounding the players, divisional races, and more - Welcome back to the IKE Packers Podcast!Help the show by telling another Packers fan! Other ways to contribute are by leaving a 5-star review on Apple Podcasts and subscribing wherever you get your podcasts.@IKE_Packers on X

On The GM Shuffle, hosts Geoff Schwartz and Marty Hurney recap the top NFL storylines from Week 15 and discuss the massive changes to the NFL Playoff Picture from the weekend. The guys also discuss the race for the postseason with the Chiefs eliminated and the Micah Parsons season-ending injury. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mike Renner and JP Acosta recap every NFL game from Sunday of Week 15! The guys discuss this week's big injuries, break down the latest playoff picture, take a look at the current 2026 NFL Draft order and much more! (00:00) Intro (00:50) Chargers 16, Chiefs 13 (8:38) Packers 26, Broncos 34 (15:55) Bills 35, Patriots 31 (21:35) Vikings 34, Cowboys 26 (29:42) Lions 34, Rams 41 (35:42) Colts 16, Seahawks 18 (42:13) Ravens 24, Bengals 0 (46:31) Jets 20, Jaguars 48 (51:17) Cardinals 20, Texans 40 (57:39) Browns 3, Bears 31 (1:01:55) Panthers 17, Saints 20 (1:08:13) Titans 24, 49ers 27 (1:11:56) Raiders 0, Eagles 31 (1:14:42) Commanders 29, Giants 21 Pushing the Pile is available for free on the Audacy app as well as Apple Podcasts, Spotify and wherever else you listen to podcasts. Subscribe to our YouTube channel: https://www.youtube.com/@pushingthepile Download and Follow Pushing the Pile on Spotify: https://open.spotify.com/show/2RFkEgdbFxbPBDU5F5xEjJ?si=1062d40c04e24fd5 Follow our PTP team on Twitter: @mikerenner_, @Ky1eLong, @acosta32_jp, @pushingthepile Sign up for the Pick Six Newsletter at https://www.cbssports.com/newsletters For more NFL coverage from CBS Sports, visit https://www.cbssports.com/nfl/ To hear more from the CBS Sports Podcast Network, visit https://www.cbssports.com/podcasts/ Visit the betting arena on CBSSports.com for all the latest sportsbook reviews and sportsbook promos. You can listen to Pushing the Pile on your smart speakers! Simply say "Alexa, play the latest episode of the Pushing the Pile podcast" or "Hey Google, play the latest episode of the Pushing the Pile podcast." To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

(0:00) Patrick Mahomes tears ACL, Ravens beat Bengals, What's next for the Chiefs? (25:16) Bills beat Patriots, Was the loss good for New England? (43:27) Micah Parsons tears ACL, Is the Packers' season over? (49:52) What's Mahomes' injury mean for the Chiefs' future? (01:11:35) Brou grades Cowboys following loss to Vikings (01:24:08) Broncos beat Patriots, Can they win the Super Bowl? (01:29:06) Caleb Williams outplays Shedeur Sanders, Chiefs eliminated from playoffs (01:52:27) Can the Packers still make a playoff run?  (02:04:09) He Said, We Said (02:11:17) Steelers vs. Dolphins preview, How much pressure is on Aaron Rodgers?  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time to get up off a sorrowful Sunday, several of the NFL's most glamorous stars go down, we'll tell you what it means for their teams and their league! Meanwhile - this was fun while it lasted- but the D in Big D stands for Done - Dallas down and out - we'll tell you where it all went wrong! And - old man Rivers falls in a thriller - might've been the most consequential Sunday of the season and we're all over it all morning long! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Joe Ostrowski and Sam Panayotovich recap and react to all of yesterday's NFL action, which saw a brutal injury day as both Patrtick Mahomes and Micah Parsons go down with torn ACL's. Plus, the Chiefs are eliminated from playoff contention, the Bills come through for Sam, and more!

TSN NFL Analyst Luke Willson joined OverDrive to discuss the Bills' incredible win against the Patriots, Josh Allen in the MVP race, Patrick Mahomes' torn ACL injury and the team's dynasty, Micah Parsons' season-ending injury and the Super Bowl window and more.

Deshaun Watson returns to practice for the Cleveland Browns. Daniel Jones continues to battle a fractured fibula. And first place on the line in AFC North (Steelers vs. Ravens), the AFC South (Colts vs. Jaguars) and the NFC North (Bears vs. Packers). So much drama! Thankfully, we have Sports Illustrated NFL Staff Writer Matt Verderame to walk us through the Top Six NFL Games of Week 14. Then Pro Bowler and future Hall of Famer Von Miller stops by for a can't miss discussion on the state of pro football. (He has a new pod out, too. Give Free Range a listen.) Dave Dameshek and The Super Fuentes Brothers have all you need to plan your weekend right on Football America! (Photo by Kyusung Gong/AP) Timestamps: (00:27) The Best 31 in Sports + Pick Six (03:56) Von Miller (25:10) Top Six NFL Games with Matt Verderame AUDIO Football America! is available wherever you listen to podcasts. Leave us a 5-star review on Apple Podcasts: https://podcasts.apple.com/us/podcast/football-america/id1831757512 Follow us: Dave Dameshek: https://x.com/dameshek Matt Verderame: https://x.com/MattVerderame Von Miller: https://www.youtube.com/@VMStudio58 Host: Dave Dameshek Guests: Von Miller, Matt Verderame Team: Gino Fuentes, Mike Fuentes, Bradley Campbell Director: Danny Benitez Senior Producers: Gino Fuentes, Mike Fuentes Executive Producer: Bradley Campbell Arizona Cardinals, Atlanta Falcons, Baltimore Ravens, Buffalo Bills, Carolina Panthers, Chicago Bears, Cincinnati Bengals, Cleveland Browns, Dallas Cowboys, Denver Broncos, Detroit Lions, Green Bay Packers, Houston Texans, Indianapolis Colts, Jacksonville Jaguars, Kansas City Chiefs, Las Vegas Raiders, Los Angeles Chargers, Los Angeles Rams, Miami Dolphins, Minnesota Vikings, New England Patriots, New Orleans Saints, New York Giants, New York Jets, Philadelphia Eagles, Pittsburgh Steelers, San Francisco 49ers, Seattle Seahawks, Tampa Bay Buccaneers, Tennessee Titans, Washington Commanders Learn more about your ad choices. Visit podcastchoices.com/adchoices